Skip to main content

Table 2 Differences between treatment modalities as per the 2005 St. Gallen guidelines

From: A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study

Risk Category Endocrine responsive Endocrine response uncertain Endocrine nonresponsive
Low risk ET or Nil ET or Nil Not applicable
Intermediate risk ET alone, or CT → ET CT
CT → ET (CT + ET)
(CT + ET)  
High risk CT → ET CT → ET CT
  (CT + ET) (CT + ET)  
  1. Abbreviations: ET, endocrine therapy; Nil, no adjuvant systemic therapy; CT, chemotherapy.